AIRLINK 74.25 Decreased By ▼ -0.04 (-0.05%)
BOP 4.93 Decreased By ▼ -0.02 (-0.4%)
CNERGY 4.34 Decreased By ▼ -0.03 (-0.69%)
DFML 39.40 Increased By ▲ 0.60 (1.55%)
DGKC 85.02 Increased By ▲ 0.20 (0.24%)
FCCL 21.20 Decreased By ▼ -0.01 (-0.05%)
FFBL 33.80 Decreased By ▼ -0.32 (-0.94%)
FFL 9.70 No Change ▼ 0.00 (0%)
GGL 10.47 Increased By ▲ 0.05 (0.48%)
HBL 112.70 Decreased By ▼ -0.30 (-0.27%)
HUBC 136.76 Increased By ▲ 0.56 (0.41%)
HUMNL 11.95 Increased By ▲ 0.05 (0.42%)
KEL 4.74 Increased By ▲ 0.03 (0.64%)
KOSM 4.45 Increased By ▲ 0.01 (0.23%)
MLCF 37.85 Increased By ▲ 0.20 (0.53%)
OGDC 137.00 Increased By ▲ 0.80 (0.59%)
PAEL 25.31 Increased By ▲ 0.21 (0.84%)
PIAA 20.00 Increased By ▲ 0.76 (3.95%)
PIBTL 6.65 Decreased By ▼ -0.06 (-0.89%)
PPL 122.18 Increased By ▲ 0.08 (0.07%)
PRL 26.70 Increased By ▲ 0.05 (0.19%)
PTC 13.85 Decreased By ▼ -0.08 (-0.57%)
SEARL 57.67 Increased By ▲ 0.45 (0.79%)
SNGP 67.30 Decreased By ▼ -0.30 (-0.44%)
SSGC 10.30 Increased By ▲ 0.05 (0.49%)
TELE 8.38 Decreased By ▼ -0.02 (-0.24%)
TPLP 11.18 Increased By ▲ 0.05 (0.45%)
TRG 63.26 Increased By ▲ 0.45 (0.72%)
UNITY 26.46 Decreased By ▼ -0.04 (-0.15%)
WTL 1.39 Increased By ▲ 0.04 (2.96%)
BR100 7,809 Decreased By -1.6 (-0.02%)
BR30 25,199 Increased By 49.1 (0.2%)
KSE100 74,885 Decreased By -71.9 (-0.1%)
KSE30 24,064 Decreased By -18.9 (-0.08%)
World

Moderna files for US authorization to use its COVID-19 vaccine in teens

  • Moderna's vaccine is already being used in the United States, the European Union and Canada for anyone over 18.
Published June 10, 2021

Moderna Inc said on Thursday it has filed for US authorization to use its COVID-19 vaccine in adolescents aged 12 to 18, the latest company to seek approval to help expand the inoculation drive in the country.

Moderna's vaccine is already being used in the United States, the European Union and Canada for anyone over 18. The drugmaker has already submitted applications to the European and Canadian health regulators seeking authorization for the vaccine's use in adolescents.

Moderna's two-shot vaccine last month was shown to be effective in adolescents aged 12-17 and showed no new or major safety problems in a clinical trial which evaluated the vaccine in 3,732 teenagers.

Vaccinating children has been considered key to achieving "herd immunity" and the US has already authorized Pfizer and German partner BioNTech SE's COVID-19 vaccine for use in children as young as 12.

Comments

Comments are closed.